	Application No. Applicant(s)			
Notice of Allowability	10/668,978	AHTING ET AL.	HTING ET AI	
	Examiner	Art Unit		
	Elvis O. Price	1621		
The MAILING DATE of this communication and claims being allowable, PROSECUTION ON THE MERITS derewith (or previously mailed), a Notice of Allowance (PTOLIOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT of the Office or upon petition by the applicant. See 37 CFR 1.	IS (OR REMAINS) CLOSED in 85) or other appropriate comments. This application is a	this application. If not include unication will be mailed in due	ed course. THIS	
. This communication is responsive to				
. 🔀 The allowed claim(s) is/are <u>1-7</u> .				
3. ⊠ The drawings filed on <u>23 September 2003</u> are accepted	d by the Examiner.			
 Acknowledgment is made of a claim for foreign priorit a) All b) Some* c) None of the: 1. Certified copies of the priority documents h 2. Certified copies of the priority documents h 3. Copies of the certified copies of the priority 	nave been received. nave been received in Application	on No	tion from the	
International Bureau (PCT Rule 17.2(a)).	documents have been receive	d in this hational stage applica	uon nom mo	
* Certified copies not received:				
Applicant has THREE MONTHS FROM THE "MAILING DA' noted below. Failure to timely comply will result in ABANDO THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.	TE" of this communication to file DNMENT of this application.	e a reply complying with the rec	quirements	
5. A SUBSTITUTE OATH OR DECLARATION must be so INFORMAL PATENT APPLICATION (PTO-152) which	ubmitted. Note the attached EX gives reason(s) why the oath o	AMINER'S AMENDMENT or Nor declaration is deficient.	OTICE OF	
6. CORRECTED DRAWINGS (as "replacement sheets")	must be submitted.	·		
(a) I including changes required by the Notice of Drafts	person's Patent Drawing Revie	w (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date	•			
(b) including changes required by the attached Exami Paper No./Mail Date	ner's Amendment / Comment o	r in the Office action of		
Identifying indicia such as the application number (see 37 C each sheet. Replacement sheet(s) should be labeled as such	FR 1.84(c)) should be written on to in the header according to 37 C	he drawings in the front (not the FR 1.121(d).	e back) of	
 DEPOSIT OF and/or INFORMATION about the d attached Examiner's comment regarding REQUIREME 	eposit of BIOLOGICAL MAT ENT FOR THE DEPOSIT OF BI	ERIAL must be submitted. I OLOGICAL MATERIAL.	Note the	
Attachment(s) 1. Notice of References Cited (PTO-892)	5. ☐ Notice of I	nformal Patent Application (PT	O-152)	
2. Notice of Draftperson's Patent Drawing Review (PTO-9	· ·	Summary (PTO-413), ./Mail Date		
3. Information Disclosure Statements (PTO-1449 or PTO/Paper No./Mail Date 9/23/03		Amendment/Comment		
1. Examiner's Comment Regarding Requirement for Depo		s Statement of Reasons for Alk	owance	
of Biological Material	9. Other	 '		

Application/Control Number: 10/668,978

Art Unit: 1621

DETAILED ACTION

Claims 1-12 are pending in the application

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1-7 drawn to a method for producing glycerin, classified in class 568, subclass 858.
- II. Claim 8, drawn to a glycerin product, classified in class 568, subclass 852.
- III. Claims 9-12, drawn to a method for deactivating prions, classified in class 422, subclass 1.

Inventions of Group I and Group II are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case, the product as claimed can be made by another and materially different process such as that disclosed in US Pat. 2156863.

The invention of Group III is distinct from the inventions of Group I or II because there is not patentable co-action between the Groups and prior art anticipating and/or rendering the invention of Group III obvious would not necessarily anticipate or render obvious the inventions of Group I or II. Thus, causing an undue burden of search.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Application/Control Number: 10/668,978

Art Unit: 1621

20

During a telephone conversation with John E. Drach on 3/10/04 a provisional election was made without traverse to prosecute the invention of Group I, claims 1-7. Affirmation of this election must be made by applicant in replying to this Office action. Claims 8-12 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to non-elected inventions.

EXAMINER'S AMENDMENT

This application is in condition for allowance except for the presence of claims 8-12, drawn to inventions non-elected without traverse. Accordingly, claims 8-12 have been cancelled. Applicants reserve the right to file Divisional applications directed to the non-elected inventions.

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

The application has been amended as follows:

Claims 8-12 have been cancelled.

Reasons for Allowance

The following is an examiner's statement of reasons for allowance: Applicants' method for producing glycerin is unobvious over the prior art of record because the prior art or record does not teach or suggest producing glycerin from a prion-contaminated fat as presently claimed, wherein the prions are deactivated (after the prion-contaminated fat is hydrolyzed) by heating the sweet water fraction in a vertical constant temperature

Page 4

Application/Control Number: 10/668,978

Art Unit: 1621

zone to a temperature of at least 200° C and allowing for a two-layer phase separation of the said sweet water fraction which is maintained at a temperature of at least 200° C until substantial deactivation of the prions occurs. All claims (1-7) are allowed.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elvis O. Price whose telephone number is 571 272-0644. The examiner can normally be reached on 8:30 am to 5:00 pm; Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johann R. Richter can be reached on 571 272-0646. The fax phone numbers for the organization where this application or proceeding is assigned is 703 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703 308-1235.

Elvis O. Price